Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16563522 | 0.90 | SMN1; SMN2 (0.48) | GLALMNAL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL3126308 | 0.88 | GLA (0.57) | GLALMNAL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL1601447 | 0.88 | GLA (0.57) | GLALMNAL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL19706848 | 0.88 | GLA (0.57) | GLALMNAL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL15426466 | 0.81 | SMN1; SMN2 (0.59) | GLALMNAL3MBTL1SMN1; SMN2TSHR | |
| SCHEMBL9693862 | 0.80 | LMNA (0.52) | GLALMNAL3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL1699215 | 0.80 | LMNA (0.61) | GLALMNAL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL1917376 | 0.78 | GLA (0.52) | GLALMNAL3MBTL1TP53TSHR | |
| SCHEMBL6643658 | 0.77 | SMN1; SMN2 (0.49) | GLALMNAL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL16563397 | 0.77 | GLA (0.46) | GLALMNAL3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9527841-B2 | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2873669-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-0255217-B1 | FUSED IMIDAZOHETEROCYCLIC COMPOUNDS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4948800-A | MUSCLE RELAXANTS; ANTICONVULSANTS; ANXIOLYTIC AGENTS; 3-HYDROXYALKYL-PYRIDO(4,5-B OR-C)IMIDAZOLE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-14 | — | — | US | disclosed |
| US-4914109-A | ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| US-4873251-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-10 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | GLA 156/4885LMNA 3778/4885L3MBTL1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.